Quarterly report pursuant to Section 13 or 15(d)
Cover
Cover
Financial Statements
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (unaudited)
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (unaudited)
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (unaudited) (Parenthetical)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) (Parenthetical)
Notes to Financial Statements
BUSINESS
SIGNIFICANT ACCOUNTING POLICIES
PROPERTY AND EQUIPMENT, NET
FAIR VALUE MEASUREMENTS
STOCKHOLDERS??? EQUITY
TEMPORARY EQUITY
ASSET PURCHASE AGREEMENT WITH KATANA
ASSET PURCHASE AGREEMENT WITH TRIGEMINA
ASSET PURCHASE AGREEMENT WITH TRIMARAN
LICENSE AGREEMENT WITH UNIVERSITY OF ALBERTA
LICENSE AGREEMENT WITH OYAGEN
LICENSE AGREEMENT WITH INSERM
LICENSE AGREEMENTS WITH COLUMBIA UNIVERSITY
SALE OF COMMON STOCK
STOCK-BASED COMPENSATION
STOCK WARRANTS
LEASES
COMMITMENTS
SUBSEQUENT EVENTS
Accounting Policies
SIGNIFICANT ACCOUNTING POLICIES (Policies)
Notes Tables
SIGNIFICANT ACCOUNTING POLICIES (Tables)
PROPERTY AND EQUIPMENT, NET (Tables)
TEMPORARY EQUITY (Tables)
STOCK-BASED COMPENSATION (Tables)
STOCK WARRANTS (Tables)
LEASES (Tables)
Notes Details
BUSINESS (Details Narrative)
The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same amounts shown in the condensed consolidated statement of cash flows: (D
Potentially dilutive securities excluded from the computation of basic and diluted net loss per share, as of June 30, 2022 and 2021, are as follows: (Details)
SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)
Property and equipment, net consisted of the following (in thousands): (Details)
PROPERTY AND EQUIPMENT, NET (Details Narrative)
FAIR VALUE MEASUREMENTS (Details Narrative)
STOCKHOLDERS??? EQUITY (Details Narrative)
As of June 30, 2022, Series A and Series B preferred shares reflected on the balance sheet is reconciled on the following table (in thousands): (Details)
TEMPORARY EQUITY (Details Narrative)
ASSET PURCHASE AGREEMENT WITH KATANA (Details Narrative)
ASSET PURCHASE AGREEMENT WITH TRIGEMINA (Details Narrative)
ASSET PURCHASE AGREEMENT WITH TRIMARAN (Details Narrative)
LICENSE AGREEMENT WITH OYAGEN (Details Narrative)
LICENSE AGREEMENT WITH INSERM (Details Narrative)
LICENSE AGREEMENTS WITH COLUMBIA UNIVERSITY (Details Narrative)
SALE OF COMMON STOCK (Details Narrative)
A summary of the stock option activity and related information for the Plans for the six months ended June 30, 2022 is as follows: (Details)
The assumptions used in the valuation of stock options granted during the six months ended June 30, 2022 and 2021 were as follows: (Details)
STOCK-BASED COMPENSATION (Details Narrative)
The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at June 30, 2022: (Details)
STOCK WARRANTS (Details Narrative)
At June 30, 2022, future minimum lease payments for operating leases with non-cancelable terms of more than one year were as follows (in thousands): (Details)
Other information related to leases is as follows: (Details)
LEASES (Details Narrative)
COMMITMENTS (Details Narrative)
SUBSEQUENT EVENTS (Details Narrative)
LEASES